Vebotolimab with ptorlimab for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs for advanced bile duct or gallbladder cancer that has EGFR protein on tumor cells and has not responded to previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced or spread and confirmed by biopsy.
- Your tumor must have at least some EGFR protein (score 1+ or higher).
- You must have had at least one prior cancer treatment that did not work.
- You must be able to perform daily activities with little or no help (ECOG 0-1).
- Your blood counts, kidney, and liver function must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This study tests whether combining two immunotherapy drugs—pucotenlimab (a PD-1 inhibitor that boosts your immune system) and becotatugvedotin (an antibody-drug that targets EGFR cancer cells)—can shrink advanced cholangiocarcinoma (bile duct or gallbladder cancer). The goal is to see if this combination works better and is safe for patients whose cancer cannot be surgically removed or has spread.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests two new drugs (becotatug vedotin and pucotenlimab) together for advanced biliary tract cancer—a cancer of the bile ducts or gallbladder. The drugs may help if your cancer has a specific marker (EGFR) and has not responded to earlier treatments.
This trial tests a combination of a cancer-fighting virus (H101), a targeted therapy (lenvatinib), and an immunotherapy (toripalimab) against a standard chemotherapy (FOLFOX) for people with advanced biliary tract cancer that has progressed after one prior treatment. The goal is to see if the new combination is more effective.
This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy (GemOX) and lenvatinib can shrink tumors enough so that bile duct or gallbladder cancers that could not be removed initially become eligible for surgery. It is an option for people with advanced but not yet spread cancer who have not received prior treatment.
Hear when a new Cancer of Biliary Duct trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.